Objective:

To evaluate the effectiveness and safety of aminolevulinic acid photodynamic therapy (ALA-PDT) for HPV-associated cervical intraepithelial neoplasia grade I (CIN I) and to determine optimal treatment parameters.

Approach:

• Study Design: 240 patients diagnosed with CIN I were divided into four groups based on ALA application time and light exposure duration, receiving treatment every 2 weeks for four sessions.
• Treatment Groups: Group A1: 3-hour application, 30-minute light exposure; Group A2: 3-hour application, 40-minute light exposure; Group B1: 5-hour application, 30-minute light exposure; Group B2: 5-hour application, 40-minute light exposure.
• Follow-Up: Patients were followed for 12 months post-treatment, with assessments at 3 and 6 months for HPV testing, TCT, and colposcopy.

Key Findings:

• Significant decrease in HPV positivity rates and increase in negative conversion rates at 3 and 6 months across all groups.
• Group B2 showed the greatest improvements in treatment outcomes.
• Group B2 had the highest cure rate and lowest recurrence rate.
• HPV16 and HPV18 were positively correlated with the cure rate.

Interpretation:

ALA-PDT is reported to be effective for treating HPV-associated CIN I, with identified treatment parameters of a 5-hour ALA application and 40-minute light exposure.

Limitations:

• The study did not assess long-term outcomes beyond 12 months.
• The sample size for each group may limit the generalizability of the findings.

Conclusion:

ALA-PDT demonstrates efficacy in treating HPV-related CIN I.